Federal Circuit Clarifies Joint Ownership Rules with a 'Resounding Yes'
Client Alert | 1 min read | 10.10.08
An inventor of one or more claims of a patent is an co-owner of the entire patent even without contribution to all of the claims, a Federal Circuit panel concludes in Lucent Tech., Inc. v. Gateway, Inc. (No. 2007-1546, -1580; September 25, 2008).
To counter Lucent's infringement claim, Microsoft alleged that Lucent lacked standing because Fraunhofer allegedly co-owned the patent. Microsoft based its allegation on a joint development agreement ("JDA"). Under the JDA, the Federal Circuit found Lucent's predecessor, AT&T, had developed two claims of a patent and that two other claims were jointly developed with Fraunhofer. Despite this finding, Lucent relied on the century-old Supreme Court precedent holding that a patent owner cannot split up its ownership rights and assign different claims to different parties. Under this precedent in view of the JDA, Lucent argued that it owned the patent, and that Fraunhofer was merely a licensee, not a co-owner.
Applying more-recent Federal Circuit precedent - but ruling consistent with the older Supreme Court authorities - the Federal Circuit phrases the issue as "whether Fraunhofer is the owner of the '080 patent even though it did not contribute to the invention of some of the claims." The answer is a "resounding yes," according to the Federal Circuit, which holds that Lucent lacked standing in the absence of Fraunhofer. The Federal Circuit also provides some prospective guidance to future joint development participants, noting that AT&T had the option to file separate patent applications.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
Client Alert | 2 min read | 09.11.26
New ISOO Guidance Directs Federal Agencies to Provide More CUI Guidance to Contractors

